Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bifidobacterium infantis + lactobacillus acidophilus + enterococcus faecalis
- Development stage
- Unknown
- Lead developer
- Sine Pharmaceutical
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
This combination is a live biotherapeutic product consisting of three symbiotic bacteria: Bifidobacterium infantis, Lactobacillus acidophilus, and Enterococcus faecalis. It is primarily indicated for the treatment of intestinal flora imbalance-related conditions such as acute and chronic diarrhea, constipation, and abdominal distension. Upon oral administration, these bacteria colonize different segments of the gastrointestinal tract, where they produce organic acids (lactic and acetic acid), lower the local pH, and create an environment hostile to pathogenic bacteria like Escherichia coli and Shigella. Additionally, the combination helps restore the mucosal barrier and stimulates local immune responses, thereby promoting overall gut health and homeostasis. The three strains work synergistically: the facultative anaerobes (L. acidophilus and E. faecalis) consume oxygen to create an anaerobic environment conducive to the growth of the obligate anaerobe (B. infantis).
- Brand names
- PeifeikangBifid Triple Viable
- Other names
- Bifidobacterium infantis, Lactobacillus acidophilus, and Enterococcus faecalis combinationTriple Viable Probiotics
Beyond the preview
Go deeper on bifidobacterium infantis + lactobacillus acidophilus + enterococcus faecalis.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bifidobacterium infantis + lactobacillus acidophilus + enterococcus faecalis.